XML 45 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory
Components of selected captions in the consolidated condensed balance sheets consisted of the following:
September 30, 2022December 31, 2021
Inventories
Raw materials$143.7 $132.8 
Work in process172.7 164.3 
Finished products441.4 429.6 
$757.8 $726.7 
Schedule of Accounts Payable and Accrued Liabilities
September 30, 2022December 31, 2021
Accrued and other liabilities 
Employee compensation and withholdings$250.0 $319.7 
Taxes payable38.6 30.6 
Property, payroll, and other taxes54.8 68.9 
Research and development accruals71.6 58.2 
Accrued rebates91.8 77.0 
Fair value of derivatives4.4 3.9 
Accrued marketing expenses15.3 20.1 
Legal and insurance (a)
81.1 79.1 
Accrued relocation costs25.9 26.2 
Accrued professional services11.2 11.9 
Accrued realignment reserves16.2 19.1 
Other accrued liabilities78.6 87.6 
$739.5 $802.3 
_______________________________________
(a)     On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries to, among other things, settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. As of September 30, 2022, $51.3 million was accrued in "Accrued and other liabilities" and $153.9 million was accrued in "Litigation settlement accrual" on the consolidated condensed balance sheet.
Schedule of Cash Flow, Supplemental Disclosures
Supplemental Cash Flow Information
(in millions)
Nine Months Ended
September 30,
20222021
Cash paid during the year for:
Income taxes$315.9 $112.6 
Amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
$22.2 $24.1 
Non-cash investing and financing transactions:  
Right-of-use assets obtained in exchange for new lease liabilities$24.7 $13.5 
Capital expenditures accruals$25.3 $20.1 
Conversion of notes receivable to equity investment$— $21.5 
Schedule of Cash and Cash Equivalents
Cash, Cash Equivalents, and Restricted Cash
(in millions)
September 30, 2022December 31, 2021
Cash and cash equivalents$1,247.8 $862.8 
Restricted cash included in other current assets1.1 1.5 
Restricted cash included in other assets2.8 3.1 
Total cash, cash equivalents, and restricted cash$1,251.7 $867.4 
Schedule of Restricted Cash
Cash, Cash Equivalents, and Restricted Cash
(in millions)
September 30, 2022December 31, 2021
Cash and cash equivalents$1,247.8 $862.8 
Restricted cash included in other current assets1.1 1.5 
Restricted cash included in other assets2.8 3.1 
Total cash, cash equivalents, and restricted cash$1,251.7 $867.4